ArticleCase reports in oncology
Penile Metastasis as a First Manifestation of Metastatic Castrate-Resistant Prostate Cancer: A Case Report and Review of Management Challenges.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Penis is a rare site of metastasis of prostate cancer, with an incidence of 0.3%. Penile metastasis is often detected incidentally via imaging modalities. Symptomatic cases may present with penile nodules, deformity, or urinary symptoms, and a biopsy is required for confirmation. Treatment varies based on disease extent and patient condition, ranging from tumour-directed approaches (penectomy, radiotherapy) to systemic therapies. Case Presentation: A 69-year-old man with high-risk nonmetastatic prostate cancer (T3bN0M0) underwent pelvic radiotherapy and androgen deprivation therapy. Five months later, he presented with urinary difficulty and penile pain. Imaging revealed multiple nodules within corpora cavernosa, along with lung lesions suggesting metastatic disease. A biopsy confirmed penile metastasis from prostate adenocarcinoma (Gleason score 9). Following a multidisciplinary team discussion, penectomy was ruled out, and the patient underwent palliative radiotherapy (RT), 20 Gy in 5 fractions, followed by systemic chemotherapy with docetaxel and carboplatin. Despite four cycles of chemotherapy, the disease progressed into the lungs, and the patient's performance status declined. The patient was transitioned to palliative care and passed away 12 months after the diagnosis of penile metastasis. Conclusion: Penile metastasis from prostate cancer is rare but an aggressive entity with a median survival ranging from 6 to 18 months. Penile metastasis shall be in the differentials when patients present with priapism, penile pain, and urinary difficulty. Tumour-directed approaches, including surgery and RT, could be curative. Emerging therapies such as stereotactic body radiotherapy and PSMA-targeted radioligand therapy may improve outcomes for this rare and aggressive manifestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.